Skip to main content

Heart failure

24-04-2023 | Heart failure | News

Prescription NSAID use may trigger heart failure in type 2 diabetes

A case-crossover study supports a link between use of non-steroidal anti-inflammatory drugs and development of heart failure in people with type 2 diabetes.

08-02-2023 | Heart failure | News

Meta-analysis shows mixed picture for GLP-1 receptor agonists in heart failure

A meta-analysis suggests that glucagon-like peptide-1 receptor agonists may help prevent new-onset heart failure in people with type 2 diabetes.

20-12-2022 | Dapagliflozin | News

Dapagliflozin on way to EC approval for all heart failure

Click through to read more on this announcement

06-12-2022 | Empagliflozin | News

Empagliflozin benefits supported for mid-range ejection fraction

A prespecified analysis of EMPEROR-Preserved indicates benefits of empagliflozin for people with heart failure and mildly reduced or preserved left ventricular ejection fraction.

Human heart with ecg graph. 3d illustration

18-11-2022 | Dapagliflozin | News

Dapagliflozin HFpEF benefits independent of glucose levels

People who have heart failure with preserved ejection fraction benefit from dapagliflozin irrespective of whether they have normal or impaired glucose metabolism, shows further analysis of DELIVER.

02-09-2022 | Dapagliflozin | News

DELIVER results round-up: Frailty, AF, recent hospitalization, and more

A flurry of publications accompanying the primary findings of DELIVER shows dapagliflozin to benefit a wide range of people who have heart failure with preserved ejection fraction.

Clinician holding a clear tablet with a heart image - cardiovascular research concept

31-08-2022 | Heart failure | News

‘Strikingly consistent’ evidence for SGLT2 inhibitor benefits across the spectrum of heart failure

SGLT2 inhibitors reduce the risk for adverse outcomes in a broad range of patients with heart failure, suggest findings from a meta-analysis of five randomized placebo-controlled trials.

27-08-2022 | Dapagliflozin | News

Dapagliflozin DELIVERs improved HFpEF outcomes

Dapagliflozin significantly reduces the risk for worsening heart failure or cardiovascular death in people who have heart failure with preserved ejection fraction, show the results of the DELIVER trial.